{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicigodgdaexknfilwq67h323kkqxybrsmfwmzdosonbjctensohm4",
    "uri": "at://did:plc:o7x3aaueo7gbdj5s6ywwl7sl/app.bsky.feed.post/3mgh3a6wykhf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibhdflbiez2f5ibeu2uymwtyulki2vejk6xpbq5bf4n3kzfywezoy"
    },
    "mimeType": "image/jpeg",
    "size": 99207
  },
  "path": "/aspen-pharmacare-targets-canadian-market-with-ozempic-generic-by-q3-2026/?utm_source=rss&utm_medium=rss&utm_campaign=aspen-pharmacare-targets-canadian-market-with-ozempic-generic-by-q3-2026",
  "publishedAt": "2026-03-06T20:43:18.000Z",
  "site": "https://thedeepdive.ca",
  "tags": [
    "Biotech",
    "Latest",
    "Ozempic",
    "semaglutide",
    "weightloss",
    "Aspen Pharmacare Targets Canadian Market with Ozempic Generic by Q3 2026",
    "the deep dive"
  ],
  "textContent": "\n\nAspen Pharmacare, a South African drugmaker, plans to enter the Canadian market with a generic version of Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic by the third quarter of 2026. The move aims to capitalize on the soaring demand for GLP-1 receptor agonists amid a global shortage of the branded medication. The company is […]\n\nThe post Aspen Pharmacare Targets Canadian Market with Ozempic Generic by Q3 2026 appeared first on the deep dive.",
  "title": "Aspen Pharmacare Targets Canadian Market with Ozempic Generic by Q3 2026"
}